智通财经APP讯，兆科眼科-B(06622)发布截至2025年6月30日止6个月的中期业绩，该集团取得收益1580.3万元，同比减少68.25%;净亏损1.17亿元，同比增加53.85%。
公告称，亏损增加主要是由于并无上一期间根据一项产品许可协议确认的一次性许可收入所致。此外，由于BRIMOCHOL™ PF及CARBACHOL™ PF的第I及第II期临床试验展开，以及环孢素眼用凝胶的新一轮第III期临床试验开始，导致研发开支增加，继而抵销报告期内行政费用持续减少的部分影响。
收益减少主要是由于公司改变销售策略所致。公司更为着重扩大眼科药物的分销网络，同时重组销售团队，集中于主要销售地区。因此，整体销售额于报告期内短暂及阶段性下跌。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.